Publications
160
Citations
4,023
Est. group size
~18
Recurring co-author estimate
Active years
30
Publishing since 1997
Typically publishes in teams of ~27 · 0% small-team papers (≤3 authors) · across 9 venues
- Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study
Blood Advances · 2024
- Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy
Haematologica · 2024
- Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long‐Term Outcomes in a Prospective, Single‐Arm Trial
Arthritis & Rheumatology · 2024
- A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis
Blood Advances · 2023
- A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care (SOC) Versus Placebo Plus SOC in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (E-CELERATE; NCT05181540): Trial in Progress
Transplantation and Cellular Therapy · 2023
- Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors
JAMA Oncology · 2022
- Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes
Transplantation and Cellular Therapy · 2021
- Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma
Transplantation and Cellular Therapy · 2021
- Results of an Open Label Dose Escalation Trial of AB-205 (E-CEL® cells) in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT)
Transplantation and Cellular Therapy · 2021
- A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes
Biology of Blood and Marrow Transplantation · 2020
- Results of a Phase 1 Open Label Dose Escalation Trial of AB-205 (Allogeneic Engineered Endothelial Cell Therapy) in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT)
Blood · 2020
- Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States
Blood · 2017
- Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report
Cancer · 2017
- Allogeneic haematopoietic cell transplantation for extranodal natural killer/T‐cell lymphoma, nasal type: a <scp>CIBMTR</scp> analysis
British Journal of Haematology · 2017
- Biology of Blood and Marrow Transplantation×19
- Transplantation and Cellular Therapy×14
- Blood×13
- Blood Advances×11
- Bone Marrow Transplantation×5
- David Frame
Medicine · University of Michigan
- Steven M. Devine
Medicine · The Ohio State University
- Ayman Saad
Medicine · The Ohio State University
- Marcos de Lima
Medicine · The Ohio State University
- Sarah Wall
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile